Is KRYS undervalued or overvalued?
As of 2025-03-16, the Intrinsic Value of Krystal Biotech Inc (KRYS) is 47.60 USD. This KRYS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 179.38 USD, the upside of Krystal Biotech Inc is -73.50%. This means that KRYS is overvalued by 73.50%.
The range of the Intrinsic Value is 31.68 - 206.12 USD
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 31.68 - 206.12 | 47.60 | -73.5% |
| DCF (Growth 10y) | 33.99 - 210.72 | 50.29 | -72.0% |
| DCF (EBITDA 5y) | 52.55 - 64.69 | 58.94 | -67.1% |
| DCF (EBITDA 10y) | 50.11 - 68.14 | 58.79 | -67.2% |
| Fair Value | 77.37 - 77.37 | 77.37 | -56.87% |
| P/E | 106.84 - 169.10 | 143.78 | -19.8% |
| EV/EBITDA | 64.69 - 192.61 | 124.06 | -30.8% |
| EPV | 6.22 - 2.63 | 4.42 | -97.5% |
| DDM - Stable | 18.71 - 109.69 | 64.20 | -64.2% |
| DDM - Multi | 15.44 - 79.52 | 26.85 | -85.0% |
| Market Cap (mil) | 5,167.94 |
| Beta | 1.29 |
| Outstanding shares (mil) | 28.81 |
| Enterprise Value (mil) | 4,823.07 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.06% |
| Cost of Debt | 5.00% |
| WACC | 7.36% |